AR077820A1 - Inhibidores de las jnk - Google Patents

Inhibidores de las jnk

Info

Publication number
AR077820A1
AR077820A1 ARP100102908A ARP100102908A AR077820A1 AR 077820 A1 AR077820 A1 AR 077820A1 AR P100102908 A ARP100102908 A AR P100102908A AR P100102908 A ARP100102908 A AR P100102908A AR 077820 A1 AR077820 A1 AR 077820A1
Authority
AR
Argentina
Prior art keywords
hydroxy
alkyl
haloalkyl
lower alkyl
alkoxy
Prior art date
Application number
ARP100102908A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR077820A1 publication Critical patent/AR077820A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen métodos y formulaciones para inhibir las JNK y tratar los trastornos mediados por las JNK y similares, con los compuestos y procesos para obtener dichos compuestos, y las correspondientes composiciones, aquí descritas. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo, en la que: Y, es CH o N; X es CH o N; cada X1 es con independencia halogeno, alquilo inferior, alcoxi inferior, haloalquilo inferior o hidroxi; m es el numero 0, 1 o 2; X2 es H, alquilo inferior, alcoxi inferior, amido, haloalquilo inferior o haloalcoxi inferior; X3 es alquilo inferior, alcoxi inferior o haloalquilo inferior; p es el numero 0 o 1; cada X4 es con independencia alquilo inferior, alcoxi inferior, haloalquilo inferior, hidroxi, hidroxialquilo inferior, OC(=O)Z2 o halogeno; q es el numero 0, 1 o 2; X5 es alquilo inferior; s es el numero 0, 1 o 2; r es el numero 0 o 1; Y es H, OH, C(=O)Z2, C(=O)OZ2, OZ2, OC(=O)Z2, N(Z1)C(=O)(Z2), C(Z1)2S(O)2Z2, N(Z1)S(O)2Z2, N(Z1)S(O)2N(Z1)(Z2), C(Z1)2(Z2) o (C=O)N(Z1)(Z2); Z1 es H o Z1'; Z1' es alquilo inferior, opcionalmente sustituido por uno o más Z1ö; cada Z1ö es con independencia halogeno, hidroxi, haloalquilo inferior, dialquilamino o amino; Z2 es H o Z2'; Z2' es hidroxi, alquilo inferior, alcoxi inferior, hidroxialquilo inferior, haloalquilo inferior, cicloalquilo, cicloalquil-alquilo inferior, heterocicloalquilo, heterocicloalquil-alquilo inferior, opcionalmente sustituido por uno o más Z2ö; cada Z2ö es con independencia halogeno, hidroxi, alquilo inferior, cicloalquilo, ciano, haloalquilo inferior, amino, ácido carboxílico, éster o alcoxi inferior; R1 es un enlace, C(=O), C(=O)O, C(=O)CH2OC(=O), C(=O)CH2NHC(=O)O o S(=O)2; R2 es H o R2'; R2' es hidroxi, alquilo inferior, N(R3)2, hidroxialquilo inferior o haloalquilo inferior, opcionalmente sustituido por uno o más R2ö; cada R2ö es con independencia ciano, amino, dialquilamino, hidroxi, hidroxialquilo inferior o alcoxi inferior; y cada R3 es con independencia H, alquilo inferior, cicloalquilo inferior, fenilo, heterocicloalquilo inferior o los dos R3 juntos forman un anillo heterocíclico; con la condicion de que si X es N, X2 es H, Y' es CH, R1 es C(=O), R2 es metilo, r es el numero 1, m es el numero 0, p es el numero 0, q es el numero 0, Y es N(Z1)S(O)2Z2, y Z2 es metilo, entonces Z1 no sea H ni hidroxietilo.
ARP100102908A 2009-08-10 2010-08-09 Inhibidores de las jnk AR077820A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23252209P 2009-08-10 2009-08-10

Publications (1)

Publication Number Publication Date
AR077820A1 true AR077820A1 (es) 2011-09-28

Family

ID=42710723

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102908A AR077820A1 (es) 2009-08-10 2010-08-09 Inhibidores de las jnk

Country Status (15)

Country Link
US (1) US8536172B2 (es)
EP (1) EP2464640A1 (es)
JP (1) JP5784604B2 (es)
KR (1) KR101506318B1 (es)
CN (1) CN102471319B (es)
AR (1) AR077820A1 (es)
AU (1) AU2010283769B2 (es)
BR (1) BR112012003059A2 (es)
CA (1) CA2768749A1 (es)
IL (1) IL217756A0 (es)
IN (1) IN2012DN01231A (es)
MX (1) MX2012001449A (es)
SG (1) SG178321A1 (es)
TW (1) TW201109336A (es)
WO (1) WO2011018417A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151357A1 (en) * 2010-06-04 2011-12-08 F. Hoffmann-La Roche Ag Inhibitors of jnk
MX2015000908A (es) * 2012-07-20 2015-09-21 Cleave Biosciences Inc Pirimidinas fusionadas como inhibidores del complejo p97.
CA2903275A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
SG11201608242XA (en) 2014-04-04 2016-10-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101177729B1 (ko) * 2006-09-08 2012-09-07 에프. 호프만-라 로슈 아게 벤조트리아졸 키나아제 조절제
CN101547917A (zh) * 2006-12-08 2009-09-30 霍夫曼-拉罗奇有限公司 用作jnk调节剂的取代的嘧啶类化合物及它们的应用

Also Published As

Publication number Publication date
BR112012003059A2 (pt) 2016-08-02
JP5784604B2 (ja) 2015-09-24
IL217756A0 (en) 2012-03-29
US8536172B2 (en) 2013-09-17
TW201109336A (en) 2011-03-16
CN102471319A (zh) 2012-05-23
IN2012DN01231A (es) 2015-05-15
AU2010283769A1 (en) 2012-02-09
MX2012001449A (es) 2012-03-26
SG178321A1 (en) 2012-03-29
CA2768749A1 (en) 2011-02-17
CN102471319B (zh) 2014-06-18
KR20120055645A (ko) 2012-05-31
EP2464640A1 (en) 2012-06-20
JP2013501746A (ja) 2013-01-17
AU2010283769B2 (en) 2015-09-17
WO2011018417A1 (en) 2011-02-17
US20110034470A1 (en) 2011-02-10
KR101506318B1 (ko) 2015-03-26

Similar Documents

Publication Publication Date Title
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
MX2012003499A (es) Inhibidores de demetilasa-1 especificos de lisina y su uso.
UA117151C2 (uk) N-ациліміногетероциклічні сполуки
MX2020007722A (es) Inhibidores de endonucleasa cap-dependientes.
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
RS54708B1 (en) ARYLETINYL DERIVATIVES
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
EA201200189A1 (ru) Фуразанобензимидазолы в качестве пролекарств для лечения опухолевых или аутоиммунных заболеваний
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
CO6801736A2 (es) Derivados heterocíclicos de amina
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
UA108510C2 (en) Cyclopropane compound
AR078270A1 (es) Inhibidores de jak (quinasas janus)
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
MY143245A (en) 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
AR077820A1 (es) Inhibidores de las jnk
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
ECSP14013296A (es) Derivados de etinilo
DK2125736T3 (da) Substituerede acetophenoner egnede som PDE4-inhibitorer
AR083017A1 (es) Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5

Legal Events

Date Code Title Description
FB Suspension of granting procedure